English | Español

Abbvie
Press release submission | Jul 24, 2021

DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients

Press release submission | Aug 15, 2020

ABBVIE: New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients
Press release submission | Nov 26, 2018

ABBVIE: Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Press release submission | Oct 26, 2018

ABBVIE: To Assume Full Development and Commercial Control of Cystic Fibrosis Research Program
Press release submission | Sep 23, 2018

ABBVIE: Announces $5 Million Donation to Family Reach to Support Children Battling Cancer and Their Families
Carrie Bradon | Nov 28, 2017

AbbVie to take part in Evercore ISI Biopharma Catalyst conference
Kathy Adams | Nov 15, 2017

AbbVie executive to present at Jefferies London Healthcare Conference
Robert Hadley | Nov 7, 2017

FDA fast-tracking review for AbbVie’s endometriosis drug

Trending
+ Pharmaceuticals
Patient Daily | Aug 8, 2025

PhRMA Chief Public Affairs Officer on 340B abuse: ‘Big, tax-exempt hospitals in urban areas are using a loophole to qualify as “rural”’
Patient Daily | Aug 7, 2025

Dallas Breathe Free Sinus & Allergy Centers earns 4.8-star rating from 670 Google reviews
Patient Daily | Aug 4, 2025

Founder of ReKlaim Health on 340B: ‘They pocket the difference, bill insurers and patients full price and call it charity care’
Patient Daily | Aug 1, 2025

Executive director of ASAP 340B: ‘The second largest drug discount program in the country doesn't have basic transparency’